Bayer Vietnam and Vietnam National Heart Association Partner to Improve Cardiovascular Care in Vietnam

Date:

Bayer Vietnam, in collaboration with the Vietnam National Heart Association, has announced a strategic partnership to improve cardiovascular care in Vietnam. The aim of the partnership is to enhance medical knowledge, clinical skills, and patient care outcomes, particularly in the management of thrombosis-related diseases such as atrial fibrillation, venous thromboembolism, coronary artery disease, and peripheral artery disease.

Cardiovascular diseases are a significant cause of mortality in Vietnam, accounting for 31% of total deaths according to the World Health Organization (WHO). Lifestyle factors, including sedentary habits, unhealthy diets, tobacco use, increased stress levels, and an aging population, contribute to the rising incidence of cardiometabolic diseases, including thrombosis-related conditions.

The increasing demand for healthcare services and specialized interventions has led to pressure on the healthcare system, as well as financial burden on patients and their families. Effective strategies are required to prevent, detect, and manage cardiovascular diseases in a timely manner.

To address this issue, Bayer Vietnam and the Vietnam National Heart Association have launched the program Improving the Quality of Training and Management of Cardiovascular Disease for Doctors and the Community, 2024-2025. The program will organize scientific conferences and continuous medical education programs to update medical knowledge and enhance the skills of healthcare professionals, with a particular focus on building capacity at the provincial level.

Regular updates to treatment recommendations for thrombosis-related diseases will ensure that healthcare providers have access to the most advanced and effective approaches. Additionally, Bayer Vietnam’s radiology division will improve healthcare professionals’ understanding and skills in utilizing advanced imaging technologies for the precise diagnosis of cardiovascular conditions. This will enable personalized treatment plans, disease progression monitoring, and targeted care for patients, ultimately improving healthcare outcomes.

See also  Cardiac Biomarker Market Poised to Reach $38 Billion by 2033

The President of the Vietnam National Heart Association, Prof. Dr. Huynh Van Minh, stated that the collaboration with Bayer Vietnam is an important milestone in enhancing cardiovascular disease management in Vietnam. By combining resources and expertise, the association aims to develop innovative solutions, conduct impactful research, and deliver comprehensive training programs. The partnership will empower medical professionals, raise awareness in the community, and improve patient outcomes.

In addition to healthcare professional training and disease management, the partnership will focus on empowering patients with knowledge about cardiovascular diseases. Educational materials will be developed to raise public awareness about risk factors, symptoms, and prevention strategies for thrombotic diseases. By promoting a culture of proactive healthcare-seeking behaviors and patient engagement, the overall management of these diseases can be significantly improved.

Ingo Brandenburg, Managing Director of Bayer Vietnam, expressed pride in their heritage of providing new treatment options for heart and blood conditions. Bayer is committed to reducing the burden of cardiovascular diseases on families, communities, and society. They encourage the active involvement of patients and their families in prevention efforts and treatment compliance through health awareness initiatives.

The collaboration between Bayer Vietnam and the Vietnam National Heart Association comes at a crucial time when concerted efforts are needed. By combining their expertise and resources, the partnership aims to address the challenges faced by healthcare professionals, patients, and the healthcare system. Through research, education, and comprehensive programs, the collaboration endeavors to improve the prevention, diagnosis, and management of cardiovascular diseases and enhance the health and well-being of the Vietnamese population.

See also  GenAI Revolution: How Businesses Embrace AI to Drive Innovation and Growth

Bayer Vietnam is proud to be one of the sponsors for the 27th Congress of the ASEAN Federation of Cardiology, hosted by the Vietnam National Heart Association. The congress focuses on managing cardiovascular diseases amidst multiple comorbidities and utilizing advanced interventions, technology, artificial intelligence, and telemedicine. The partnership between the Vietnam National Heart Association and Bayer Vietnam was officially announced during the event through the signing of a memorandum of understanding (MoU) to strengthen collaborations in advancing cardiovascular care and improving patient outcomes.

The Vietnam National Heart Association is a non-profit professional organization aiming to promote cardiovascular health, welfare, and well-being among the Vietnamese population. Their objective is to share information, knowledge, and experience among cardiologists in Vietnam.

Overall, the partnership between Bayer Vietnam and the Vietnam National Heart Association holds promise in improving cardiovascular care in Vietnam. Through collaborative efforts, research advancements, and public awareness initiatives, the prevention, management, and overall outcomes of cardiovascular diseases are expected to improve, benefiting the Vietnamese population.

Frequently Asked Questions (FAQs) Related to the Above News

What is the purpose of the partnership between Bayer Vietnam and the Vietnam National Heart Association?

The partnership aims to improve cardiovascular care in Vietnam by enhancing medical knowledge, clinical skills, and patient care outcomes, particularly in the management of thrombosis-related diseases.

What are some of the thrombosis-related diseases that the partnership focuses on?

The partnership focuses on diseases such as atrial fibrillation, venous thromboembolism, coronary artery disease, and peripheral artery disease.

Why are cardiovascular diseases a significant concern in Vietnam?

Cardiovascular diseases account for 31% of total deaths in Vietnam, and this percentage is rising due to lifestyle factors, an aging population, and other risk factors such as sedentary habits, unhealthy diets, tobacco use, and increased stress levels.

How does the partnership plan to address the increasing demand for healthcare services and specialized interventions?

The partnership plans to organize scientific conferences and continuous medical education programs to update medical knowledge and enhance the skills of healthcare professionals, with a particular focus on building capacity at the provincial level.

How will the partnership ensure that healthcare providers have access to the most advanced and effective approaches for thrombosis-related diseases?

Regular updates to treatment recommendations will be provided, ensuring that healthcare providers have access to the most advanced and effective approaches for thrombosis-related diseases.

How will Bayer Vietnam's radiology division contribute to the partnership?

Bayer Vietnam's radiology division will improve healthcare professionals' understanding and skills in utilizing advanced imaging technologies for the precise diagnosis of cardiovascular conditions, enabling personalized treatment plans and targeted care for patients.

What role will education play in the partnership?

The partnership will develop educational materials to raise public awareness about risk factors, symptoms, and prevention strategies for thrombotic diseases, empowering patients with knowledge about cardiovascular diseases.

How does Bayer Vietnam aim to reduce the burden of cardiovascular diseases on families, communities, and society?

Bayer Vietnam encourages the active involvement of patients and their families in prevention efforts and treatment compliance through health awareness initiatives.

What is the Vietnam National Heart Association's objective?

The Vietnam National Heart Association aims to promote cardiovascular health, welfare, and well-being among the Vietnamese population by sharing information, knowledge, and experience among cardiologists in Vietnam.

What are the expected outcomes of the partnership between Bayer Vietnam and the Vietnam National Heart Association?

Through collaborative efforts, research advancements, and public awareness initiatives, the partnership aims to improve the prevention, management, and overall outcomes of cardiovascular diseases in Vietnam, benefiting the Vietnamese population.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

HCLTech Partners with Arm on Custom AI Silicon Chips Revolutionizing Data Centers

HCLTech partners with Arm to revolutionize data centers with custom AI chips, optimizing AI workloads for efficiency and performance.

EDA Launches Tender for Advanced UAS Integration in European Airspace

EDA launches tender for advanced UAS integration in European airspace. Enhancing operational resilience and navigation accuracy. Register now!

Ethereum ETF Approval Sparks WienerAI Frenzy for 100x Gains!

Get ready for 100x gains with WienerAI as potential Ethereum ETF approval sparks frenzy for ETH investors! Don't miss out on this opportunity.

BBVA Launches Innovative AI Program with ChatGPT to Revolutionize Business Operations

BBVA partners with OpenAI to revolutionize business operations through innovative ChatGPT AI program, enhancing productivity and innovation.